1. Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment. Issue 7 (18th March 2022) Authors: Guo, Cen; Yu, Yanke; Chakrabarti, Jayeta; Piha‐Paul, Sarina A.; Moroose, Rebecca; Plotka, Anna; Shi, Haihong; Durairaj, Chandrasekar; Wang, Diane D.; Wainberg, Zev A. Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 7(2022) Page Start: 3392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. (28th May 2020) Authors: Elmeliegy, Mohamed; Yu, Yanke; Litton, Jennifer K.; Czibere, Akos; Wilson, Gary G.; Tudor, Iulia Cristina; Zheng, Jenny; Wang, Diane D. Journal: Journal of clinical pharmacology Issue: Volume 60:Number 10(2020) Page Start: 1334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pharmacodynamic Modeling of CDK4/6 Inhibition‐Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression‐Free Survival in Patients With Advanced Breast Cancer. (16th November 2021) Authors: Yu, Yanke; Sun, Wan; Liu, Yuan; Wang, Diane Journal: Journal of clinical pharmacology Issue: Volume 62:Number 3(2022) Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Physiologically Based Pharmacokinetic Modeling of Palbociclib. (22nd August 2016) Authors: Yu, Yanke; Loi, Cho‐Ming; Hoffman, Justin; Wang, Diane Journal: Journal of clinical pharmacology Issue: Volume 57:Number 2(2017) Page Start: 173 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer. (6th September 2019) Authors: Yu, Yanke; Durairaj, Chandrasekar; Shi, Haihong; Wang, Diane D. Journal: Journal of clinical pharmacology Issue: Volume 60:Number 2(2020) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ‐secretase modulator, E2212, in healthy human subjects. (2nd January 2014) Authors: Yu, Yanke; Logovinsky, Veronika; Schuck, Edgar; Kaplow, June; Chang, Min‐kun; Miyagawa, Takehiko; Wong, Nancy; Ferry, Jim Journal: Journal of clinical pharmacology Issue: Volume 54:Number 5(2014:May) Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial. (28th May 2020) Authors: Yu, Yanke; Elmeliegy, Mohamed; Litton, Jennifer K.; Tudor, Iulia Cristina; Czibere, Akos; Zheng, Jenny; Wang, Diane D. Journal: Journal of clinical pharmacology Issue: Volume 60:Number 10(2020) Page Start: 1324 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The Utility of a Population Approach in Drug–Drug Interaction Assessments: A Simulation Evaluation. (17th May 2017) Authors: Wang, Diane D.; Yu, Yanke; Kassir, Nastya; Zhu, Min; Hanley, William D.; Earp, Justin C.; Chow, Andrew T.; Gupta, Manish; Hu, Chuanpu Journal: Journal of clinical pharmacology Issue: Volume 57:Number 10(2017) Page Start: 1268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗